Program
netarsudil
Also written as “AR-13324 Ophthalmic Solution 0.02%”, “Netarsudil Ophthalmic Solution 0.02%” and “Netarsudil ophthalmic solution 0.02%”.
Its studies are mostly in Glaucoma, Open-Angle · Glaucoma · Fuchs' Endothelial Dystrophy · Corneal Edema, led by 2 companies.
Drug pageNetarsudil: every studyAll 33 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Alconits history only | 180 open or running | phase 4since Jan 10, 2019 | Feb 5, 2012 | none ahead |
| Price Vision Group | 20 open or running | phase 3since May 30, 2019 | May 30, 2019 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Price Vision Group only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Jun 9, 2015Named netarsudilINNProposed as its International Nonproprietary Name in WHO's List 113
- May 30, 2019First study: phase 3 study in Fuchs' Endothelial DystrophyFirst studyNCT03971357 · 19 enrolled · United States
- Aug 7, 2019Phase 3 study in Fuchs' Endothelial DystrophyNCT04051463 · 29 enrolled · United States
TargetBeta
“Rho-associated protein kinase inhibitor”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| belumosudilrule | Sanofi | phase 4 | 26 |
Studies
All 2 Price Vision Group leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT04051463Fuchs' Endothelial Dystrophy · United States | 3 | Completed | Jul 1, 2020 | 29 |
| NCT03971357Fuchs' Endothelial Dystrophy · United States | 3 | Terminated | Aug 26, 2021 | 19 |
How it is read
Names in the registry
- “AR-13324 Ophthalmic Solution 0.02%”, 7 entries
- “Netarsudil Ophthalmic Solution 0.02%”, 3 entries
- “Netarsudil ophthalmic solution 0.02%”, 2 entries
- “Netarsudil Ophthalmic”, 2 entries
- “AR-13324 Ophthalmic Solution 0.04%”, 2 entries
Conditions, from the studies’ own filings
- Glaucoma, Open-Angle, 13 studies
- Glaucoma, 2 studies
- Fuchs' Endothelial Dystrophy, 2 studies
- Corneal Edema, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.